Smith Laura, Venella Kimberly
Children's Hospital of Philadelphia.
Clin J Oncol Nurs. 2017 Apr 1;21(2 Suppl):29-34. doi: 10.1188/17.CJON.S2.29-34.
BACKGROUND: Pediatric patients with relapsed and refractory acute lymphoblastic leukemia are more often being treated with chimeric antigen receptor (CAR) T-cell therapy. As with any new therapy, the management of this patient population has a unique set of challenges. The side effects of this therapy can range from mild to severe, with cytokine release syndrome being the most common reason for hospitalization. .
OBJECTIVES: This article presents common side effects, treatments, and challenges of caring for hospitalized patients who have received CAR T-cell therapy. .
METHODS: A case study is used to illustrate a patient's inpatient hospitalization course after receiving CAR T-cell therapy, including the management of treatment-related toxicities. .
As treatments emerge, nurses will be challenged with learning the associated side effects and toxicities. CAR T-cell therapy can result in a unique trajectory of potential symptoms and the potential for complete resolution of disease.
复发和难治性急性淋巴细胞白血病的儿科患者越来越多地接受嵌合抗原受体（CAR）T细胞疗法治疗。与任何新疗法一样，对这一患者群体的管理存在一系列独特的挑战。这种疗法的副作用从轻度到重度不等，细胞因子释放综合征是住院的最常见原因。
本文介绍了接受CAR T细胞疗法的住院患者常见的副作用、治疗方法及护理挑战。
通过一个案例研究来说明患者接受CAR T细胞疗法后的住院病程，包括治疗相关毒性的管理。
随着治疗方法的出现，护士将面临了解相关副作用和毒性的挑战。CAR T细胞疗法可导致潜在症状的独特病程以及疾病完全缓解的可能性。
